RT Journal Article
SR Electronic
T1 Prevalence of Macroprolactin in Hyperprolactinemic patients receiving Anti-psychotics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.11.21256928
DO 10.1101/2021.05.11.21256928
A1 Al Wasify, Loai Ali Al Mortada
A1 Al Maamary, Shaikha Said
A1 Al Tobi, Mohammed Nasser Rashid
YR 2021
UL http://medrxiv.org/content/early/2021/05/11/2021.05.11.21256928.abstract
AB Background Prolactin (PRL) hormone circulates in the blood in three forms, mono-prolactin which constitutes 85 % of prolactin in healthy and hyperprolactinemia conditions, a dimeric prolactin (big PRL) and polymeric PRL (big-big prolactin or Macroprolactin). Macroprolactin in normal conditions is not exceeding 2% of the total serum prolactin and had no biological activity. In some cases, of hyperprolactinemia the dominant form becomes MaPRL and exceeding the 2% percentage of total leading to misdiagnosis of hyperprolactinemia and un-necessary radiological investigations. The aim of this study is to detect the prevalence of MaPRL in Psychiatric patients with hyperprolactinemia due to anti-psychotic medications at Al Masarra hospital.Material and methods The study was conducted on 190 samples from patients with high prolactin in Al Masarra Hospital either inpatients or out-patient clinics either male or non-lactating not pregnant female. The measurement of Prolactin level was measured by the automated analyser COBAS e411, Roche Diagnostic. Macroprolactin was precipitated by using Polyethylene glycol (PEG).Results Prevalence of Macroprolactin was 10.5 % of hyperprolactinemic patients receiving antipsychotics. There was a statistically significant difference in gender between the symptomatic and asymptomatic group. There was no significant difference in medications used between the symptomatic and asymptomatic group and there was a statistically significant difference in total Prolactin & Macroprolactin between males and females.Conclusions Investigation for Macroprolactin should be done in every hyperprolactinemia patient who is receiving antipsychotics more especially the asymptomatic cases to avoid unnecessary radiological imaging and treatment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was not a clinical trial, it was a retrospective study of the hyperprolactinemic patients who were receiving antipsychotics.Funding StatementThis research did not receive any grants from any funding agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:on 12 April, 2020 I got a letter from the Directorate General of Health services - Governorate of Muscat - Ministry of Health - Sultanate of Oman informing me that our study is approved by the regional research and ethics committee. The letter was signed by the Chairperson of regional research committee. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all data of the study are available upon request.PRLProlactinMaPRLMacroprolactinPEGPolyethylene glycolIgGImmunoglobulin GRRRecovery rateGFCGel Filtration Chromatography